Many studies are being done to evaluate different tests that can more accurately tell which patients would benefit from chemo and which patients could avoid it. Some studies are looking at if these CTCs can be removed and then tested in the lab to determine which specific anticancer drugs will work on the tumor. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. An interim analysis of the PALOMA3 trial shows that palbociclib plus fulvestrant extends the progression-free survival of some women with hormone receptor-positive metastatic breast cancer. Sometimes there are significant side effects long- and short-term from chemotherapy, so having tests that can determine who really needs chemo would be useful. Women who received the investigational drug trastuzumab emtansine T-DM1 lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine Xeloda and the targeted drug lapatinib Tykerb.